European Innovation Council

The European Innovation Council (EIC), established in 2020 and headquartered in Brussels, Belgium, is dedicated to supporting high-potential innovators, entrepreneurs, small enterprises, and researchers. Its primary focus is on fostering early-stage startups that demonstrate significant environmental, social, and governance (ESG) impacts. The EIC collaborates with private investors to co-invest in ventures, particularly within the deep technology sector, aiming to drive innovation and sustainable development across Europe. By providing financial backing and resources, the EIC seeks to enhance the growth potential of promising startups and contribute to a more innovative and competitive European economy.

David Malo Jean

Director

Candace Johnson

President

Past deals in Southern Europe

VSORA

Venture Round in 2025
VSORA is an intellectual property provider based in France, specializing in digital signal processing (DSP) technology for chipmakers focused on next-generation digital communications systems, particularly 5G networks. Established in 2015 by a team of experienced DSP engineers, the company offers a powerful multi-core DSP architecture that eliminates the necessity for DSP co-processors, thereby enhancing design flexibility. VSORA's innovative DSP development flow enables collaboration between signal processing engineers and software engineers, allowing them to work within the same environment and share source code, which significantly accelerates the time-to-market for new products. The company's mission is to address technical challenges by optimizing DSP computing power while minimizing power consumption and silicon footprint, thereby improving overall system performance.

Wooptix

Series C in 2025
Wooptix S.L., founded in 2014 and headquartered in Madrid, Spain, specializes in advanced imaging technologies. The company develops light field and wavefront phase imaging software that captures comprehensive information about light, utilizing the full resolution of sensors. This innovative platform allows for three-dimensional modulation of images across various camera setups, producing volumetric images and videos with enhanced data points and high frame rates. By focusing on improving human interaction with the environment, Wooptix aims to redefine the way users perceive and engage with their surroundings, offering new possibilities for image quality and post-processing capabilities.

TENSIVE

Series A in 2025
TENSIVE s.r.l. is a biomedical company based in Milan, Italy, founded in 2012. It specializes in the development of innovative prostheses for natural breast reconstruction and augmentation. The company's products utilize biodegradable synthetic biomaterials and feature an internal micro-architecture that mimics blood vessel structures. These vascularized prostheses aim to enhance the quality of life for patients undergoing treatment for breast cancer, offering a solution that reduces the need for recurrent and costly surgical interventions. Through its focus on advanced biomaterials and design, TENSIVE seeks to provide effective and sustainable options for breast reconstruction.

Onward

Grant in 2024
Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.

INBRAIN Neuroelectronics

Series B in 2024
INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

Axelera AI

Series B in 2024
Axelera AI focuses on providing specialized hardware and software platforms to enhance artificial intelligence tasks, particularly in edge computing. Its primary product, the Metis™ AI Platform, combines hardware and software to offer high-performance, energy-efficient AI inference solutions. The platform's innovative design has earned recognition as a CES® 2024 Innovation Awards Honoree. Established in 2021 after incubation by Bitfury and collaboration with imec, Axelera AI is headquartered in the AI Innovation Center at the High Tech Campus in Eindhoven, with research and development offices in Belgium, Switzerland, and Italy. The company's team comprises experts in AI from leading firms and Fortune 500 companies, focusing on delivering sustainable edge applications through a custom dataflow architecture and multicore in-memory computing that minimizes power consumption.

Tilkal

Venture Round in 2024
Tilkal is a Paris-based company founded in 2017 that specializes in supply chain traceability through its innovative software platform. This platform utilizes a B2B blockchain network to facilitate secure and verifiable data sharing among various supply chain stakeholders. Tilkal’s software captures traceability data from physical products in a ledger, enabling companies to obtain real-time insights into their supply chains. Customers leverage the platform to address critical questions regarding product location, sourcing risks, ESG commitments, and compliance verification. Notable clients include Danone, Daher, Joone, and the Responsible Mica Initiative, among others. The Tilkal network comprises over 70 independent nodes, with nearly 700 companies actively participating to share and analyze data, thereby enhancing the resilience, sustainability, and ethical standards of their supply chains.

Multiverse Computing

Series A in 2024
Multiverse Computing SL is a software development company based in San Sebastian, Spain, with an additional office in Toronto, Canada. Founded in 2019, the company specializes in creating quantum computing software that addresses complex financial and macro-economic challenges. Its products are tailored for various applications, including portfolio optimization, risk analysis, and market simulation. By leveraging probabilistic and nondeterministic technologies, Multiverse Computing aims to help organizations across diverse sectors such as banking, energy, manufacturing, and logistics navigate the complexities of the second quantum revolution, ultimately providing them with a competitive advantage in their respective industries.

Daze

Series A in 2024
Daze is an Italian hi-tech startup developing smart chargers for electric vehicles (EVs). Founded in 2016, Daze spent 3 years mainly focusing on pure R&D activities to create the first both autonomous and conductive charger for EVs: DazePlug. During 2020 Daze has also developed, started to produce and sell two “classic” EV charging products: DazeBox (for home charging) and DazeMax (for shared charging). In 2021 product sales exceeded 3,800 units and revenues approached 1.9 million Euro, with CAGR of 330% between 2019 and 2021. From June 2021 the company is also benefitting from a grant of 2.5 million Euro from the European Innovation Council (EIC) Fund, which is and will be used to push forward DazePlug development. In 2022 revenues grow over 5 million Euro with positive EBITDA, Daze Iberica started the operations. 2023 is the year of expansion, Daze France is starting the operations and new business models and new products are added to the business

Palobiofarma

Venture Round in 2024
Palobiofarma is a Spanish biotechnology company based in Barcelona's Science Park, dedicated to the discovery and development of new drugs that target adenosine receptors. The company aims to be a leader in adenosine drug discovery in Europe by focusing on innovative therapies. Palobiofarma specializes in creating selective adenosine receptor modulators, with a particular emphasis on addressing advanced prostate cancer. By leveraging medicinal chemistry and in vitro pharmacology, the company is working towards bringing its first marketed drug to the medical community, supporting healthcare professionals in their efforts to treat this challenging disease.

NETRIS Pharma

Series A in 2023
NETRIS Pharma S.A.S. is a biotechnology company based in Lyon, France, that specializes in identifying and developing therapeutic molecules aimed at treating cancer. The company's innovative approach focuses on targeting dependence receptors, which are trans-membrane proteins that play a crucial role in signaling within cells and regulating tumor development. NETRIS Pharma offers both in vitro and in vivo research services, along with preclinical practices, to advance drug manufacturing for various types of cancer, including breast cancer, lung cancer, glioblastoma, and neuroblastoma. Founded in 2008, the company is dedicated to contributing to the pharmaceutical industry by developing novel cancer therapies.

Antabio

Series B in 2023
Antabio is a private biopharmaceutical company based in Labege, France, focused on developing novel treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating antibacterial resistance-breakers that can restore the efficacy of existing antibiotics. Its key innovation includes inhibitors of bacterial metalloenzymes, specifically Metallo ß-lactamases (MBLs), which are designed to be used in combination with carbapenems to address significant treatment gaps in drug-resistant nosocomial infections. Antabio aims to provide health professionals with effective medicinal products to combat life-threatening respiratory infections, including carbapenem-resistant pneumonia and chronic pulmonary diseases. The company has received recognition for its research efforts, including a Wellcome Trust Seeding Drug Discovery Award.

VSORA

Grant in 2023
VSORA is an intellectual property provider based in France, specializing in digital signal processing (DSP) technology for chipmakers focused on next-generation digital communications systems, particularly 5G networks. Established in 2015 by a team of experienced DSP engineers, the company offers a powerful multi-core DSP architecture that eliminates the necessity for DSP co-processors, thereby enhancing design flexibility. VSORA's innovative DSP development flow enables collaboration between signal processing engineers and software engineers, allowing them to work within the same environment and share source code, which significantly accelerates the time-to-market for new products. The company's mission is to address technical challenges by optimizing DSP computing power while minimizing power consumption and silicon footprint, thereby improving overall system performance.

INBRAIN Neuroelectronics

Grant in 2023
INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

Wooptix

Series B in 2023
Wooptix S.L., founded in 2014 and headquartered in Madrid, Spain, specializes in advanced imaging technologies. The company develops light field and wavefront phase imaging software that captures comprehensive information about light, utilizing the full resolution of sensors. This innovative platform allows for three-dimensional modulation of images across various camera setups, producing volumetric images and videos with enhanced data points and high frame rates. By focusing on improving human interaction with the environment, Wooptix aims to redefine the way users perceive and engage with their surroundings, offering new possibilities for image quality and post-processing capabilities.

Energy Dome

Series B in 2023
Energy Dome is an Italian company based in Lonate Pozzolo that specializes in long-duration electricity storage using liquid carbon dioxide. The company has developed a low-cost and efficient technology that employs a closed-loop thermodynamic process to store energy, making renewable power more dispatchable. By focusing on energy storage solutions, Energy Dome aims to facilitate the transition to renewable energy and contribute to the decarbonization of the energy industry. Its innovative approach seeks to address climate change challenges by significantly reducing greenhouse gas emissions, thereby promoting a more sustainable future.

ADmit Therapeutics

Venture Round in 2023
ADmit Therapeutics, S.L. is a biotechnology company focused on developing diagnostic tests for the early detection of Alzheimer's disease. Established in 2017 and based in Begues, Spain, the company utilizes an epigenetic analysis of blood samples to identify mitochondrial biomarkers, which are not related to traditional indicators such as ß-amyloid or tau proteins. The test employs next-generation sequencing to analyze various methylcytosines in mitochondrial DNA, providing medical practitioners with an accessible method for detecting early-stage Alzheimer's. This innovative approach not only aids in diagnosis but also supports pharmaceutical companies in accelerating the identification of potential curative treatments.

Voiseed

Venture Round in 2023
Voiseed is an Italian startup focused on artificial intelligence for synthetic speech, specifically designed for the video game industry. The company has developed a scalable AI Dubbing Platform that utilizes advanced generative AI technologies to create virtual human voices with expressive emotional nuances and prosody. This cloud-based software enables users to customize vocal expressions and perform multilingual voice conversions, significantly simplifying the dubbing process. By offering a universal voice model and an emotional data set, Voiseed helps creators efficiently design unique voice textures, thereby reducing costs, time, and complexity in various audio-visual projects. The company is actively expanding its features to cater to additional industries beyond gaming.

Ganymed Robotics

Series B in 2023
Ganymed Robotics SAS is a medical device company based in Paris, France, established in 2018. The company specializes in developing advanced robotics technologies and software aimed at enhancing surgical precision in orthopedic procedures, particularly focusing on knee replacement surgeries. Its innovative therapeutic device is designed to improve patient outcomes and streamline the surgical process, enabling orthopedic surgeons to reduce operating times and enhance their overall experience. By integrating robotics into surgical practices, Ganymed Robotics aims to advance the efficiency of care delivery in the orthopedic field.

Daze

Convertible Note in 2022
Daze is an Italian hi-tech startup developing smart chargers for electric vehicles (EVs). Founded in 2016, Daze spent 3 years mainly focusing on pure R&D activities to create the first both autonomous and conductive charger for EVs: DazePlug. During 2020 Daze has also developed, started to produce and sell two “classic” EV charging products: DazeBox (for home charging) and DazeMax (for shared charging). In 2021 product sales exceeded 3,800 units and revenues approached 1.9 million Euro, with CAGR of 330% between 2019 and 2021. From June 2021 the company is also benefitting from a grant of 2.5 million Euro from the European Innovation Council (EIC) Fund, which is and will be used to push forward DazePlug development. In 2022 revenues grow over 5 million Euro with positive EBITDA, Daze Iberica started the operations. 2023 is the year of expansion, Daze France is starting the operations and new business models and new products are added to the business

Energy Dome

Grant in 2022
Energy Dome is an Italian company based in Lonate Pozzolo that specializes in long-duration electricity storage using liquid carbon dioxide. The company has developed a low-cost and efficient technology that employs a closed-loop thermodynamic process to store energy, making renewable power more dispatchable. By focusing on energy storage solutions, Energy Dome aims to facilitate the transition to renewable energy and contribute to the decarbonization of the energy industry. Its innovative approach seeks to address climate change challenges by significantly reducing greenhouse gas emissions, thereby promoting a more sustainable future.

CARMAT

Grant in 2022
CARMAT is a France-based medtech company that specializes in the development and manufacture of bioprosthetic artificial hearts aimed at treating patients with severe heart failure. Founded in 2008 and located in Vélizy-Villacoublay, the company produces biocompatible and auto-regulated total artificial hearts that closely mimic the human heart's functionality. These devices are designed for individuals experiencing chronic terminal heart failure classified as NYHA class IV or those suffering from acute terminal heart failure following a major heart attack. CARMAT's innovative solutions target patients who are not suitable for heart transplantation and have exhausted other treatment options, providing a reliable new therapeutic alternative. In addition to the artificial hearts, CARMAT also develops the associated power supply and control systems, including remote diagnosis capabilities.

ELEM Biotech

Pre Seed Round in 2022
ELEM Biotech SL is a biomedical software company based in Barcelona, Spain, that specializes in creating virtual human beings using advanced mathematical modeling and cloud computing. Founded in 2018 by researchers from the Barcelona Supercomputing Center, ELEM has developed Alya Red, a suite of simulation tools designed for the medical device and pharmaceutical industries. Utilizing a Software-as-a-Service model, Alya Red allows for the simulation of cardiovascular and respiratory systems on virtual patients. By integrating high-performance computing, computational biomechanics, and data analysis, ELEM's technology enables biomedical companies and clinicians to improve diagnoses, plan treatments, and optimize drug delivery and medical devices.

INBRAIN Neuroelectronics

Grant in 2022
INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

Nexdot

Pre Seed Round in 2022
Nexdot specializes in the synthesis, production, and application of advanced semiconductor nanocrystals known as Quantum Dots (QDs), with a focus on nanoplatelets—two-dimensional nanosheet Quantum Dots that exhibit enhanced properties. Founded as a spin-off from a leading academic laboratory in Paris, Nexdot leverages over a decade of research in nanomaterials to create proprietary materials with controlled shape and composition. These innovations are poised to transform various industries, including displays, lighting, energy storage, detectors, and bio-imaging. Additionally, Nexdot is developing quantum pearl encapsulation technology to enhance the integration of quantum plates into existing production processes, thereby ensuring compliance with environmental regulations. The company is comprised of a dynamic team of skilled scientists and seasoned executives, dedicated to advancing innovation in the field of nanotechnology.

Newronika

Grant in 2022
Newronika is a company focused on restoring brain and body functions through innovative neuro-modulation technologies. It develops therapeutic devices that utilize a retro-activity system to record brain activity and modulate neuro-stimulation. By collecting, analyzing, and interpreting bio-signals, Newronika enables patients to receive timely stimulation, allowing them to engage in normal daily activities and enhance their quality of life. As a spin-off from prominent Italian research institutions, including the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Hospital and the University of Milan, Newronika benefits from a multidisciplinary team of experts in various fields such as neuroscience, neurophysiology, biomedical engineering, and neuropsychology.

CARMAT

Post in 2022
CARMAT is a France-based medtech company that specializes in the development and manufacture of bioprosthetic artificial hearts aimed at treating patients with severe heart failure. Founded in 2008 and located in Vélizy-Villacoublay, the company produces biocompatible and auto-regulated total artificial hearts that closely mimic the human heart's functionality. These devices are designed for individuals experiencing chronic terminal heart failure classified as NYHA class IV or those suffering from acute terminal heart failure following a major heart attack. CARMAT's innovative solutions target patients who are not suitable for heart transplantation and have exhausted other treatment options, providing a reliable new therapeutic alternative. In addition to the artificial hearts, CARMAT also develops the associated power supply and control systems, including remote diagnosis capabilities.

INBRAIN Neuroelectronics

Venture Round in 2022
INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

Cailabs

Series C in 2022
Cailabs is a French deep tech company based in Rennes, specializing in the design and production of photonic solutions that optimize the use of light in various applications. The company focuses on light shaping components, including mode multiplexers and converters for fiber optic networks, utilizing its patented Multi-Plane Light Conversion (MPLC) technology to reshape both single-mode and multi-mode coherent beams. Cailabs offers products tailored for telecommunications research and development, as well as multi-mode fiber link upgrades for enterprise networks. Additionally, the company provides integrated solutions for the industrial laser sector, such as laser beam shapers and combiners for material processing, and mode-selective multiplexers for EDFA arrays. Founded in 2013, Cailabs aims to address critical industrial challenges through its innovative optical components and expertise.

ROSI

Series A in 2022
ROSI is a company that develops innovative raw material recycling and revalorization technologies for the photovoltaic industry. The technologies allow for the recovery of ultra-pure silicon and other metals that are currently lost during photovoltaic cell manufacturing and at the end of the solar panel's life cycle. ROSI is based in Grenoble, France.

Energy Dome

Venture Round in 2022
Energy Dome is an Italian company based in Lonate Pozzolo that specializes in long-duration electricity storage using liquid carbon dioxide. The company has developed a low-cost and efficient technology that employs a closed-loop thermodynamic process to store energy, making renewable power more dispatchable. By focusing on energy storage solutions, Energy Dome aims to facilitate the transition to renewable energy and contribute to the decarbonization of the energy industry. Its innovative approach seeks to address climate change challenges by significantly reducing greenhouse gas emissions, thereby promoting a more sustainable future.

Fineheart

Series C in 2022
Fineheart is a France-based medical device company that specializes in innovative technologies aimed at addressing cardiovascular diseases. The company is developing an implantable cardiac device that is wirelessly powered and fully implantable, designed to provide mechanical circulatory support. This novel device optimizes cardiac output while preserving the heart's natural contractility, thereby enabling patients with heart failure to restore normal cardiac function and improve their quality of life. Fineheart's focus on advanced medical solutions positions it as a key player in the evolving landscape of cardiovascular care.

Fineheart

Grant in 2022
Fineheart is a France-based medical device company that specializes in innovative technologies aimed at addressing cardiovascular diseases. The company is developing an implantable cardiac device that is wirelessly powered and fully implantable, designed to provide mechanical circulatory support. This novel device optimizes cardiac output while preserving the heart's natural contractility, thereby enabling patients with heart failure to restore normal cardiac function and improve their quality of life. Fineheart's focus on advanced medical solutions positions it as a key player in the evolving landscape of cardiovascular care.

Tilkal

Venture Round in 2022
Tilkal is a Paris-based company founded in 2017 that specializes in supply chain traceability through its innovative software platform. This platform utilizes a B2B blockchain network to facilitate secure and verifiable data sharing among various supply chain stakeholders. Tilkal’s software captures traceability data from physical products in a ledger, enabling companies to obtain real-time insights into their supply chains. Customers leverage the platform to address critical questions regarding product location, sourcing risks, ESG commitments, and compliance verification. Notable clients include Danone, Daher, Joone, and the Responsible Mica Initiative, among others. The Tilkal network comprises over 70 independent nodes, with nearly 700 companies actively participating to share and analyze data, thereby enhancing the resilience, sustainability, and ethical standards of their supply chains.

Tilkal

Grant in 2022
Tilkal is a Paris-based company founded in 2017 that specializes in supply chain traceability through its innovative software platform. This platform utilizes a B2B blockchain network to facilitate secure and verifiable data sharing among various supply chain stakeholders. Tilkal’s software captures traceability data from physical products in a ledger, enabling companies to obtain real-time insights into their supply chains. Customers leverage the platform to address critical questions regarding product location, sourcing risks, ESG commitments, and compliance verification. Notable clients include Danone, Daher, Joone, and the Responsible Mica Initiative, among others. The Tilkal network comprises over 70 independent nodes, with nearly 700 companies actively participating to share and analyze data, thereby enhancing the resilience, sustainability, and ethical standards of their supply chains.

Nexdot

Grant in 2022
Nexdot specializes in the synthesis, production, and application of advanced semiconductor nanocrystals known as Quantum Dots (QDs), with a focus on nanoplatelets—two-dimensional nanosheet Quantum Dots that exhibit enhanced properties. Founded as a spin-off from a leading academic laboratory in Paris, Nexdot leverages over a decade of research in nanomaterials to create proprietary materials with controlled shape and composition. These innovations are poised to transform various industries, including displays, lighting, energy storage, detectors, and bio-imaging. Additionally, Nexdot is developing quantum pearl encapsulation technology to enhance the integration of quantum plates into existing production processes, thereby ensuring compliance with environmental regulations. The company is comprised of a dynamic team of skilled scientists and seasoned executives, dedicated to advancing innovation in the field of nanotechnology.

ELEM Biotech

Grant in 2022
ELEM Biotech SL is a biomedical software company based in Barcelona, Spain, that specializes in creating virtual human beings using advanced mathematical modeling and cloud computing. Founded in 2018 by researchers from the Barcelona Supercomputing Center, ELEM has developed Alya Red, a suite of simulation tools designed for the medical device and pharmaceutical industries. Utilizing a Software-as-a-Service model, Alya Red allows for the simulation of cardiovascular and respiratory systems on virtual patients. By integrating high-performance computing, computational biomechanics, and data analysis, ELEM's technology enables biomedical companies and clinicians to improve diagnoses, plan treatments, and optimize drug delivery and medical devices.

Ganymed Robotics

Series B in 2022
Ganymed Robotics SAS is a medical device company based in Paris, France, established in 2018. The company specializes in developing advanced robotics technologies and software aimed at enhancing surgical precision in orthopedic procedures, particularly focusing on knee replacement surgeries. Its innovative therapeutic device is designed to improve patient outcomes and streamline the surgical process, enabling orthopedic surgeons to reduce operating times and enhance their overall experience. By integrating robotics into surgical practices, Ganymed Robotics aims to advance the efficiency of care delivery in the orthopedic field.

Onward

Grant in 2022
Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.

Abzu

Grant in 2022
Abzu is a scientific artificial intelligence company founded in January 2018, with offices in Copenhagen, Denmark, and Barcelona, Spain. The company develops the QLattice, an innovative AI platform that aims to challenge conventional black box AI by providing transparent and explainable models. Abzu's technology is designed to assist pharmaceutical and biotech companies in accelerating drug development processes. By unlocking new disease mechanisms, discovering novel biomarkers, and validating multiple targets simultaneously, Abzu enables these companies to reduce research and development costs and enhance their discovery capabilities. Through its pioneering approach, Abzu inspires data scientists to adopt a more scientific methodology in their work.

Antabio

Grant in 2022
Antabio is a private biopharmaceutical company based in Labege, France, focused on developing novel treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating antibacterial resistance-breakers that can restore the efficacy of existing antibiotics. Its key innovation includes inhibitors of bacterial metalloenzymes, specifically Metallo ß-lactamases (MBLs), which are designed to be used in combination with carbapenems to address significant treatment gaps in drug-resistant nosocomial infections. Antabio aims to provide health professionals with effective medicinal products to combat life-threatening respiratory infections, including carbapenem-resistant pneumonia and chronic pulmonary diseases. The company has received recognition for its research efforts, including a Wellcome Trust Seeding Drug Discovery Award.

Quanturi Oy

Venture Round in 2022
Quanturi Oy is a Finnish company founded in 2016 and headquartered in Espoo, specializing in continuous monitoring solutions for fermentable products. The company develops and markets connected objects and systems for data analysis, focusing on agricultural, forestry, and waste management sectors. Its product offerings include wireless monitoring systems for compost temperature, grain management, hay monitoring, and other industrial temperature applications. Quanturi Oy also sells its products online and has expanded its presence to several countries, including France, Great Britain, the Netherlands, Switzerland, Italy, and Belgium.

Qarnot

Grant in 2022
Qarnot is a French company based in Montrouge that specializes in providing economical and ecological high-performance computing (HPC) solutions through an innovative platform. It designs and develops Q.rad, a computing heater that combines microprocessors and serves as both a heat source and a computing server. This unique product not only generates heat through computation but also allows users to regulate temperature via an embedded thermostat or smartphone. Qarnot's technology aims to reduce costs associated with traditional data centers, such as infrastructure, maintenance, and cooling, by offering a disruptive alternative for construction companies seeking efficient heating solutions for new buildings. Established in 2010, Qarnot has developed three generations of computing heaters to meet the needs of its clients while promoting sustainable computing practices.

C2C NewCap

Venture Round in 2022
C2C NewCap, founded in 2014 by Rui Silva and Andre Mao de Ferro, is a Lisbon-based manufacturer specializing in the production of supercapacitors designed for efficient electrical energy storage. The company focuses on developing next-generation devices that utilize proprietary electrodes and an aqueous electrolyte, which contribute to a low environmental impact. C2C NewCap aims to provide clients with energy storage solutions that not only enhance operational efficiency but also reduce overall environmental and operational costs.

Antabio

Venture Round in 2022
Antabio is a private biopharmaceutical company based in Labege, France, focused on developing novel treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating antibacterial resistance-breakers that can restore the efficacy of existing antibiotics. Its key innovation includes inhibitors of bacterial metalloenzymes, specifically Metallo ß-lactamases (MBLs), which are designed to be used in combination with carbapenems to address significant treatment gaps in drug-resistant nosocomial infections. Antabio aims to provide health professionals with effective medicinal products to combat life-threatening respiratory infections, including carbapenem-resistant pneumonia and chronic pulmonary diseases. The company has received recognition for its research efforts, including a Wellcome Trust Seeding Drug Discovery Award.

Quanturi Oy

Grant in 2022
Quanturi Oy is a Finnish company founded in 2016 and headquartered in Espoo, specializing in continuous monitoring solutions for fermentable products. The company develops and markets connected objects and systems for data analysis, focusing on agricultural, forestry, and waste management sectors. Its product offerings include wireless monitoring systems for compost temperature, grain management, hay monitoring, and other industrial temperature applications. Quanturi Oy also sells its products online and has expanded its presence to several countries, including France, Great Britain, the Netherlands, Switzerland, Italy, and Belgium.

SiPearl

Grant in 2022
SiPearl is a French semiconductor company established in 2019, headquartered in Maisons-Laffitte, Île-de-France, with research and development centers located in France, Germany, and Spain. The company specializes in the design of high-performance, low-power microprocessors intended for exascale supercomputers, aligning its product development with the European Union’s technological goals. Its first microprocessor range, Rhea, is set for commercialization in early 2024 and is based on the Arm Neoverse V1 architecture. SiPearl is committed to manufacturing Rhea using advanced processes from TSMC, ensuring state-of-the-art performance. The microprocessors are aimed at a variety of applications, including computing, artificial intelligence, medical research, climate change mitigation, and energy management, serving scientific researchers and major players in the IT, electronics, and automotive sectors.

SiPearl

Series A in 2022
SiPearl is a French semiconductor company established in 2019, headquartered in Maisons-Laffitte, Île-de-France, with research and development centers located in France, Germany, and Spain. The company specializes in the design of high-performance, low-power microprocessors intended for exascale supercomputers, aligning its product development with the European Union’s technological goals. Its first microprocessor range, Rhea, is set for commercialization in early 2024 and is based on the Arm Neoverse V1 architecture. SiPearl is committed to manufacturing Rhea using advanced processes from TSMC, ensuring state-of-the-art performance. The microprocessors are aimed at a variety of applications, including computing, artificial intelligence, medical research, climate change mitigation, and energy management, serving scientific researchers and major players in the IT, electronics, and automotive sectors.

Qubit Pharmaceuticals

Seed Round in 2022
Qubit Pharmaceuticals is a Paris-based company founded in 2020 that specializes in drug discovery technology. Established through collaboration among notable institutions such as CNAM, CNRS, the University of Texas at Austin, Sorbonne University, and Washington University, it draws on over 20 years of research and development recognized by prestigious awards. The company has developed a drug discovery simulation platform that aims to reduce both the cost and duration of preclinical drug development. Utilizing proprietary force field models and molecular dynamics calculations, the platform conducts virtual screening and visualization to identify promising drug candidates. This innovative approach leverages quantum physics to support biopharmaceutical companies in accelerating their research and development efforts.

Core Biogenesis

Private Equity Round in 2022
Core Biogenesis is a biotechnology company based in Paris, France, established in 2020. It specializes in next-generation recombinant protein production technologies, utilizing proprietary gene editing and plant biotechnology to significantly lower the costs associated with producing growth factors. These growth factors are crucial for applications in the clean meat and cell therapy industries. The company has developed an ultra-scalable bioproduction platform that leverages plants as biofactories, enabling efficient mass production and targeted extraction of valuable bioproducts. This innovative approach not only accelerates production but also enhances the ability to regulate cell growth and increases yields, making it a valuable partner for clients in the healthcare sector.

Cailabs

Grant in 2022
Cailabs is a French deep tech company based in Rennes, specializing in the design and production of photonic solutions that optimize the use of light in various applications. The company focuses on light shaping components, including mode multiplexers and converters for fiber optic networks, utilizing its patented Multi-Plane Light Conversion (MPLC) technology to reshape both single-mode and multi-mode coherent beams. Cailabs offers products tailored for telecommunications research and development, as well as multi-mode fiber link upgrades for enterprise networks. Additionally, the company provides integrated solutions for the industrial laser sector, such as laser beam shapers and combiners for material processing, and mode-selective multiplexers for EDFA arrays. Founded in 2013, Cailabs aims to address critical industrial challenges through its innovative optical components and expertise.

SAALG Geomechanics

Grant in 2022
SAALG Geomechanics SL, founded in 2016 and based in Barcelona, Spain, specializes in developing software for real-time analysis of ground conditions during civil engineering projects. The company provides advanced geological and numerical services, including numerical model calibrations and characterization of soil and rock parameters through back-analysis and inverse analysis. Its offerings include 2D and 3D geomechanical and geotechnical simulations, primarily focused on applications such as tunnel excavations, large and deep excavations, reinforced earth retaining walls, and wellbore stability analysis. By leveraging machine learning and real-time data analysis technology, SAALG Geomechanics enables construction companies to anticipate potential risks associated with ground movement, thereby optimizing project management, minimizing risks, and enhancing efficiency.

Scipio Bioscience

Venture Round in 2022
Scipio Bioscience is a biotechnology company based in Paris, France, founded in 2017. The company specializes in manufacturing benchtop kits that provide a sample preparation solution for single-cell studies. These kits are designed for use in sequencing applications within both clinical and basic research, particularly in the field of transcriptomics. Scipio Bioscience's innovative products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating advanced analysis and research in the life sciences.

Dracula Technologies

Grant in 2022
Dracula Technologies SAS, based in Valence, France, specializes in organic photovoltaic technology aimed at providing sustainable energy solutions for low-power devices. Founded in 2011, the company has developed an innovative product called Light As Your Energetic Response (LAYER), which captures ambient light—both indoors and outdoors—and converts it into electricity. This technology enables a variety of small devices, including phones, GPS units, and lamps, to recharge autonomously, thereby eliminating the need for traditional batteries. By utilizing digital printing techniques to create efficient light-harvesting modules, Dracula Technologies enhances the reliability and operational lifespan of electronic devices such as sensors and smart building applications, contributing to a more sustainable energy future. The company operates as a subsidiary of Ardeje.

Scipio Bioscience

Grant in 2022
Scipio Bioscience is a biotechnology company based in Paris, France, founded in 2017. The company specializes in manufacturing benchtop kits that provide a sample preparation solution for single-cell studies. These kits are designed for use in sequencing applications within both clinical and basic research, particularly in the field of transcriptomics. Scipio Bioscience's innovative products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating advanced analysis and research in the life sciences.

PeekMed

Grant in 2022
PeekMed is a company based in Braga, Portugal, that specializes in 3D pre-operative planning software for orthopedic surgery. Founded in 2015 by Jaime Campos, Sara Silva, and João Pedro Ribeiro, PeekMed's system is designed to enhance the precision of surgical procedures while simultaneously reducing costs. The software allows orthopedic surgeons to plan a variety of operations, including total joint replacements, osteotomies, and fracture reductions. It enables intuitive surgical sectioning of bones to correct deformities and facilitates the planning of trauma-related surgeries. Additionally, PeekMed's platform supports the storage and retrieval of patient studies, allowing surgeons to access medical images efficiently. The output from the system can be integrated with navigation systems, 3D printers, robotics, and mobile devices, further enhancing the surgical process and patient outcomes.

Ignion

Venture Round in 2022
Ignion is an antenna innovator based in Sant Cugat del Vallès, Spain, founded in 2015. The company specializes in manufacturing multiband, multipurpose antennas that cater to mobile and wireless connectivity requirements. Its product offerings include ready-to-use antennas designed for Internet of Things applications and short-range wireless devices, particularly suited for indoor environments. Ignion's solutions allow clients to seamlessly integrate these antennas into their industrial designs, facilitating efficient connectivity in various applications.

Core Biogenesis

Grant in 2022
Core Biogenesis is a biotechnology company based in Paris, France, established in 2020. It specializes in next-generation recombinant protein production technologies, utilizing proprietary gene editing and plant biotechnology to significantly lower the costs associated with producing growth factors. These growth factors are crucial for applications in the clean meat and cell therapy industries. The company has developed an ultra-scalable bioproduction platform that leverages plants as biofactories, enabling efficient mass production and targeted extraction of valuable bioproducts. This innovative approach not only accelerates production but also enhances the ability to regulate cell growth and increases yields, making it a valuable partner for clients in the healthcare sector.

Multiverse Computing

Venture Round in 2021
Multiverse Computing SL is a software development company based in San Sebastian, Spain, with an additional office in Toronto, Canada. Founded in 2019, the company specializes in creating quantum computing software that addresses complex financial and macro-economic challenges. Its products are tailored for various applications, including portfolio optimization, risk analysis, and market simulation. By leveraging probabilistic and nondeterministic technologies, Multiverse Computing aims to help organizations across diverse sectors such as banking, energy, manufacturing, and logistics navigate the complexities of the second quantum revolution, ultimately providing them with a competitive advantage in their respective industries.

Multiverse Computing

Grant in 2021
Multiverse Computing SL is a software development company based in San Sebastian, Spain, with an additional office in Toronto, Canada. Founded in 2019, the company specializes in creating quantum computing software that addresses complex financial and macro-economic challenges. Its products are tailored for various applications, including portfolio optimization, risk analysis, and market simulation. By leveraging probabilistic and nondeterministic technologies, Multiverse Computing aims to help organizations across diverse sectors such as banking, energy, manufacturing, and logistics navigate the complexities of the second quantum revolution, ultimately providing them with a competitive advantage in their respective industries.

Aortyx

Grant in 2021
Aortyx is a pioneering company founded by researchers from the IQS School of Engineering and the Hospital Clínic de Barcelona, dedicated to developing innovative endovascular devices for the treatment of vascular diseases. The company specializes in technology that promotes tissue regeneration by closely mimicking the biomechanical environment of the aorta. Its devices are designed to create a favorable environment for cell migration and proliferation, utilizing a bioresorbable platform that closely replicates the natural dynamics of the aorta. This approach aims to enhance the effectiveness of treatments for aortic diseases, providing healthcare professionals with advanced solutions for managing these conditions.

Daze

Seed Round in 2021
Daze is an Italian hi-tech startup developing smart chargers for electric vehicles (EVs). Founded in 2016, Daze spent 3 years mainly focusing on pure R&D activities to create the first both autonomous and conductive charger for EVs: DazePlug. During 2020 Daze has also developed, started to produce and sell two “classic” EV charging products: DazeBox (for home charging) and DazeMax (for shared charging). In 2021 product sales exceeded 3,800 units and revenues approached 1.9 million Euro, with CAGR of 330% between 2019 and 2021. From June 2021 the company is also benefitting from a grant of 2.5 million Euro from the European Innovation Council (EIC) Fund, which is and will be used to push forward DazePlug development. In 2022 revenues grow over 5 million Euro with positive EBITDA, Daze Iberica started the operations. 2023 is the year of expansion, Daze France is starting the operations and new business models and new products are added to the business

Criam

Grant in 2021
Criam is a biotechnology company based in Braga, Portugal, founded in 2015. It specializes in the research and development of a medical device designed for blood type analysis and the detection of infectious diseases. The company's flagship product offers rapid and accurate testing for various conditions, including HIV, Brucella, tick fever, syphilis, mononucleosis, and meningitis. This portable device operates independently of electricity or laboratory infrastructure, making it accessible for use in diverse environments. Additionally, Criam's technology is scalable, allowing a single reader to perform multiple tests using specific cartridges and advanced computer vision algorithms. By optimizing blood testing services, Criam aims to provide timely health information and improve clinical decision-making.

EVerZom

Grant in 2021
EVerZom is a nanomedicine biotech company based in Paris, France, specializing in the large-scale manufacturing of extracellular vesicles. Founded in 2019, the company has developed a unique, GMP-compliant bioproduction platform aimed at pharmaceutical companies. This platform enables the production of various types of extracellular vesicles, including exosomes, microvesicles, and apoptotic bodies, which are essential for intercellular communication. EVerZom's products possess protective and reparative properties, making them valuable therapeutic tools in regenerative medicine and drug delivery. The company's technology is designed to assist healthcare professionals in addressing organ failure and restoring function and homeostasis.

Voiseed

Grant in 2021
Voiseed is an Italian startup focused on artificial intelligence for synthetic speech, specifically designed for the video game industry. The company has developed a scalable AI Dubbing Platform that utilizes advanced generative AI technologies to create virtual human voices with expressive emotional nuances and prosody. This cloud-based software enables users to customize vocal expressions and perform multilingual voice conversions, significantly simplifying the dubbing process. By offering a universal voice model and an emotional data set, Voiseed helps creators efficiently design unique voice textures, thereby reducing costs, time, and complexity in various audio-visual projects. The company is actively expanding its features to cater to additional industries beyond gaming.

Ganymed Robotics

Grant in 2021
Ganymed Robotics SAS is a medical device company based in Paris, France, established in 2018. The company specializes in developing advanced robotics technologies and software aimed at enhancing surgical precision in orthopedic procedures, particularly focusing on knee replacement surgeries. Its innovative therapeutic device is designed to improve patient outcomes and streamline the surgical process, enabling orthopedic surgeons to reduce operating times and enhance their overall experience. By integrating robotics into surgical practices, Ganymed Robotics aims to advance the efficiency of care delivery in the orthopedic field.

SiPearl

Grant in 2021
SiPearl is a French semiconductor company established in 2019, headquartered in Maisons-Laffitte, Île-de-France, with research and development centers located in France, Germany, and Spain. The company specializes in the design of high-performance, low-power microprocessors intended for exascale supercomputers, aligning its product development with the European Union’s technological goals. Its first microprocessor range, Rhea, is set for commercialization in early 2024 and is based on the Arm Neoverse V1 architecture. SiPearl is committed to manufacturing Rhea using advanced processes from TSMC, ensuring state-of-the-art performance. The microprocessors are aimed at a variety of applications, including computing, artificial intelligence, medical research, climate change mitigation, and energy management, serving scientific researchers and major players in the IT, electronics, and automotive sectors.

NETRIS Pharma

Venture Round in 2021
NETRIS Pharma S.A.S. is a biotechnology company based in Lyon, France, that specializes in identifying and developing therapeutic molecules aimed at treating cancer. The company's innovative approach focuses on targeting dependence receptors, which are trans-membrane proteins that play a crucial role in signaling within cells and regulating tumor development. NETRIS Pharma offers both in vitro and in vivo research services, along with preclinical practices, to advance drug manufacturing for various types of cancer, including breast cancer, lung cancer, glioblastoma, and neuroblastoma. Founded in 2008, the company is dedicated to contributing to the pharmaceutical industry by developing novel cancer therapies.

MYSPHERA

Venture Round in 2021
MYSPHERA SL is a company based in Paterna, Spain, that specializes in developing location and process visibility solutions for the healthcare sector using Internet of Things (IoT) technology and real-time location systems (RTLS). Established in 2012, MYSPHERA offers a range of IoT devices and applications designed to enhance patient care and operational efficiency in acute care hospitals, senior living facilities, and patient homes. Its solutions include tracking systems for residents and nursing services, as well as alerts for patients. The company also provides various web applications, such as MYHOSPITAL, MYNURSING, and MYLOCS, which assist healthcare professionals and administrators in managing services effectively. By delivering actionable insights through smart sensors, MYSPHERA aims to improve patient outcomes and optimize resource management across healthcare organizations in Europe, the Middle East, and Latin America.

Spika Tech

Grant in 2021
Spika Tech is a Madrid-based company established in 2015, focused on research and development in the technological sector. The company provides a range of services aimed at assisting businesses with their projects, including virtual reality, augmented reality, complex software application development, and artificial intelligence. Additionally, Spika Tech specializes in creating logos, corporate identities, presentations, websites, applications, and online stores. By leveraging the latest techniques in design and programming, Spika Tech aims to enhance the quality of development processes for its clients.

NETRIS Pharma

Grant in 2021
NETRIS Pharma S.A.S. is a biotechnology company based in Lyon, France, that specializes in identifying and developing therapeutic molecules aimed at treating cancer. The company's innovative approach focuses on targeting dependence receptors, which are trans-membrane proteins that play a crucial role in signaling within cells and regulating tumor development. NETRIS Pharma offers both in vitro and in vivo research services, along with preclinical practices, to advance drug manufacturing for various types of cancer, including breast cancer, lung cancer, glioblastoma, and neuroblastoma. Founded in 2008, the company is dedicated to contributing to the pharmaceutical industry by developing novel cancer therapies.

APIX Analytics

Grant in 2021
APIX Analytics, founded in 2014 and headquartered in Grenoble, France, specializes in developing and marketing advanced gas analyzer systems. The company focuses on creating miniaturized multigas analyzers that leverage nano-silicon technology to enhance chemical analysis across industrial, environmental, and security applications. By integrating traditional analytical processes such as gas sampling, injection, and separation of complex mixtures, APIX Analytics improves the specificity, detection, identification, and quantification of gas compounds. This innovative approach aims to support clients in meeting safety and quality standards in various sectors, particularly in renewable development.

MYSPHERA

Grant in 2021
MYSPHERA SL is a company based in Paterna, Spain, that specializes in developing location and process visibility solutions for the healthcare sector using Internet of Things (IoT) technology and real-time location systems (RTLS). Established in 2012, MYSPHERA offers a range of IoT devices and applications designed to enhance patient care and operational efficiency in acute care hospitals, senior living facilities, and patient homes. Its solutions include tracking systems for residents and nursing services, as well as alerts for patients. The company also provides various web applications, such as MYHOSPITAL, MYNURSING, and MYLOCS, which assist healthcare professionals and administrators in managing services effectively. By delivering actionable insights through smart sensors, MYSPHERA aims to improve patient outcomes and optimize resource management across healthcare organizations in Europe, the Middle East, and Latin America.

SiPearl

Venture Round in 2021
SiPearl is a French semiconductor company established in 2019, headquartered in Maisons-Laffitte, Île-de-France, with research and development centers located in France, Germany, and Spain. The company specializes in the design of high-performance, low-power microprocessors intended for exascale supercomputers, aligning its product development with the European Union’s technological goals. Its first microprocessor range, Rhea, is set for commercialization in early 2024 and is based on the Arm Neoverse V1 architecture. SiPearl is committed to manufacturing Rhea using advanced processes from TSMC, ensuring state-of-the-art performance. The microprocessors are aimed at a variety of applications, including computing, artificial intelligence, medical research, climate change mitigation, and energy management, serving scientific researchers and major players in the IT, electronics, and automotive sectors.

ENERSENS

Grant in 2021
Enersens is a firm that produces silica aerogel products. The company was founded in 2010 and is based in Les Auvergnes, France.

Epigene Labs

Grant in 2021
Over the past couple of decades, the exponential progress of sequencing technologies has allowed an increasing number of cancer patients to benefit from precision oncology. However, the aggregation, analysis, and visualization of the massive amounts of genomic data remain a major challenge for precision oncology expansion. The Epigene Labs technology platform enables cancer drug hunters to seamlessly leverage advanced artificial intelligence in transforming genomic data into actionable insights for designing precision oncology approaches. With R&D in Paris and business development in Boston, Epigene Labs operates in the setting of value-based partnerships with world leading cancer centers and high-profile biotechs.

Wooptix

Venture Round in 2021
Wooptix S.L., founded in 2014 and headquartered in Madrid, Spain, specializes in advanced imaging technologies. The company develops light field and wavefront phase imaging software that captures comprehensive information about light, utilizing the full resolution of sensors. This innovative platform allows for three-dimensional modulation of images across various camera setups, producing volumetric images and videos with enhanced data points and high frame rates. By focusing on improving human interaction with the environment, Wooptix aims to redefine the way users perceive and engage with their surroundings, offering new possibilities for image quality and post-processing capabilities.

ENERSENS

Venture Round in 2021
Enersens is a firm that produces silica aerogel products. The company was founded in 2010 and is based in Les Auvergnes, France.

PKVitality

Series A in 2021
PKVitality is a bio-wearable company based in Paris, France, that specializes in developing innovative health monitoring devices. Its flagship product, K'Watch Glucose, is a smartwatch-style continuous glucose monitoring device that employs a micro-needle sensor to allow diabetics to monitor their glucose levels painlessly and discreetly. This wearable tracker is designed to provide real-time data without the need for calibration, offering a complete history of glucose levels and sending alerts for potential hypo or hyperglycemia episodes. Additionally, PKVitality is expanding its product line to include a Continuous Lactate Monitor and multi-analyte continuous monitors, which will further enhance the capabilities of their health monitoring technology. Founded in 2017, PKVitality aims to simplify health management for individuals, particularly those with diabetes, by eliminating the discomfort associated with traditional blood tests.

Sabi Agri

Grant in 2021
Sabi Agri is an agricultural engineering company based in Saint-Beauzire, France, founded in 2017. The company specializes in designing and manufacturing electric tractors that cater to diverse agricultural needs, including market gardening, livestock farming, field crops, viticulture, and arboriculture. By providing sustainable agricultural solutions, Sabi Agri enables farmers to adopt cost-effective agroecological practices, enhancing productivity while minimizing environmental impact.

Qubit Pharmaceuticals

Grant in 2021
Qubit Pharmaceuticals is a Paris-based company founded in 2020 that specializes in drug discovery technology. Established through collaboration among notable institutions such as CNAM, CNRS, the University of Texas at Austin, Sorbonne University, and Washington University, it draws on over 20 years of research and development recognized by prestigious awards. The company has developed a drug discovery simulation platform that aims to reduce both the cost and duration of preclinical drug development. Utilizing proprietary force field models and molecular dynamics calculations, the platform conducts virtual screening and visualization to identify promising drug candidates. This innovative approach leverages quantum physics to support biopharmaceutical companies in accelerating their research and development efforts.

Aenitis Technologies

Grant in 2021
Aenitis Technologies is a French start-up founded in July 2014 by Mauricio Hoyos and Jean-Luc Aider, both researchers associated with the CNRS at the PMMH Laboratory in Paris. The company specializes in the development of medical devices aimed at enhancing cell therapy preparations. By utilizing acoustophoresis technologies, Aenitis Technologies creates innovative solutions for the separation, manipulation, and filtration of biological elements. Their focus is on addressing challenges faced by cell therapy units and blood banks, particularly in areas such as cell sorting, washing, and isolation. Aenitis Technologies aspires to lead the market in filtering and separating solutions through their advanced acoustic preparation techniques, with the ultimate goal of revolutionizing practices in public health.

Oledcomm

Grant in 2021
Oledcomm specializes in designing and developing LiFi solutions that facilitate high-speed optical wireless data communication, targeting sectors such as aerospace and industrial markets. Founded in 2012 and re-established in February 2020 by Benjamin Azoulay, the company is headquartered in Paris, France. Its product range includes LiFi transceivers and software, which enable efficient and environmentally friendly wireless communication. Oledcomm's technology converts information into binary data, similar to optical Morse code, allowing seamless connectivity for various applications in telecom, datacom, and personal electronics.

Voiseed

Venture Round in 2021
Voiseed is an Italian startup focused on artificial intelligence for synthetic speech, specifically designed for the video game industry. The company has developed a scalable AI Dubbing Platform that utilizes advanced generative AI technologies to create virtual human voices with expressive emotional nuances and prosody. This cloud-based software enables users to customize vocal expressions and perform multilingual voice conversions, significantly simplifying the dubbing process. By offering a universal voice model and an emotional data set, Voiseed helps creators efficiently design unique voice textures, thereby reducing costs, time, and complexity in various audio-visual projects. The company is actively expanding its features to cater to additional industries beyond gaming.

INBRAIN Neuroelectronics

Grant in 2021
INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

Daze

Venture Round in 2020
Daze is an Italian hi-tech startup developing smart chargers for electric vehicles (EVs). Founded in 2016, Daze spent 3 years mainly focusing on pure R&D activities to create the first both autonomous and conductive charger for EVs: DazePlug. During 2020 Daze has also developed, started to produce and sell two “classic” EV charging products: DazeBox (for home charging) and DazeMax (for shared charging). In 2021 product sales exceeded 3,800 units and revenues approached 1.9 million Euro, with CAGR of 330% between 2019 and 2021. From June 2021 the company is also benefitting from a grant of 2.5 million Euro from the European Innovation Council (EIC) Fund, which is and will be used to push forward DazePlug development. In 2022 revenues grow over 5 million Euro with positive EBITDA, Daze Iberica started the operations. 2023 is the year of expansion, Daze France is starting the operations and new business models and new products are added to the business

Aledia

Series D in 2020
Aledia SA specializes in the development and manufacturing of innovative light-emitting diodes (LEDs) utilizing a unique 3D architecture based on gallium-nitride-on-silicon microwires. Founded in 2011 and headquartered in Grenoble, France, with additional subsidiaries in Malacca, Malaysia, and Palo Alto, California, Aledia's technology employs standard 8-inch silicon wafers and existing fabrication processes, allowing for the production of LED chips at a significantly reduced cost compared to traditional planar designs. This technology supports a range of applications, including general lighting, automotive, and display technologies, specifically for mobile and microdisplays used in augmented and virtual reality environments. Aledia's focus on efficient, brighter, and cost-effective displays positions it as a key player in the LED market.

ROSI

Grant in 2020
ROSI is a company that develops innovative raw material recycling and revalorization technologies for the photovoltaic industry. The technologies allow for the recovery of ultra-pure silicon and other metals that are currently lost during photovoltaic cell manufacturing and at the end of the solar panel's life cycle. ROSI is based in Grenoble, France.

Unblur

Venture Round in 2020
Unblur develops an AI software for public emergency services such as firefighters, civil Protection and police. It offers a platform called IRIS, a modular SaaS platform specifically tailored for an incident commander. Unblur was founded in 2015 and is headquartered in Barcelona, Spain.

Unblur

Grant in 2020
Unblur develops an AI software for public emergency services such as firefighters, civil Protection and police. It offers a platform called IRIS, a modular SaaS platform specifically tailored for an incident commander. Unblur was founded in 2015 and is headquartered in Barcelona, Spain.

Qarnot

Venture Round in 2020
Qarnot is a French company based in Montrouge that specializes in providing economical and ecological high-performance computing (HPC) solutions through an innovative platform. It designs and develops Q.rad, a computing heater that combines microprocessors and serves as both a heat source and a computing server. This unique product not only generates heat through computation but also allows users to regulate temperature via an embedded thermostat or smartphone. Qarnot's technology aims to reduce costs associated with traditional data centers, such as infrastructure, maintenance, and cooling, by offering a disruptive alternative for construction companies seeking efficient heating solutions for new buildings. Established in 2010, Qarnot has developed three generations of computing heaters to meet the needs of its clients while promoting sustainable computing practices.

Ability Pharmaceuticals

Grant in 2020
Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The company develops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures. Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization.

ADmit Therapeutics

Grant in 2020
ADmit Therapeutics, S.L. is a biotechnology company focused on developing diagnostic tests for the early detection of Alzheimer's disease. Established in 2017 and based in Begues, Spain, the company utilizes an epigenetic analysis of blood samples to identify mitochondrial biomarkers, which are not related to traditional indicators such as ß-amyloid or tau proteins. The test employs next-generation sequencing to analyze various methylcytosines in mitochondrial DNA, providing medical practitioners with an accessible method for detecting early-stage Alzheimer's. This innovative approach not only aids in diagnosis but also supports pharmaceutical companies in accelerating the identification of potential curative treatments.

ADmit Therapeutics

Venture Round in 2020
ADmit Therapeutics, S.L. is a biotechnology company focused on developing diagnostic tests for the early detection of Alzheimer's disease. Established in 2017 and based in Begues, Spain, the company utilizes an epigenetic analysis of blood samples to identify mitochondrial biomarkers, which are not related to traditional indicators such as ß-amyloid or tau proteins. The test employs next-generation sequencing to analyze various methylcytosines in mitochondrial DNA, providing medical practitioners with an accessible method for detecting early-stage Alzheimer's. This innovative approach not only aids in diagnosis but also supports pharmaceutical companies in accelerating the identification of potential curative treatments.

PKVitality

Grant in 2020
PKVitality is a bio-wearable company based in Paris, France, that specializes in developing innovative health monitoring devices. Its flagship product, K'Watch Glucose, is a smartwatch-style continuous glucose monitoring device that employs a micro-needle sensor to allow diabetics to monitor their glucose levels painlessly and discreetly. This wearable tracker is designed to provide real-time data without the need for calibration, offering a complete history of glucose levels and sending alerts for potential hypo or hyperglycemia episodes. Additionally, PKVitality is expanding its product line to include a Continuous Lactate Monitor and multi-analyte continuous monitors, which will further enhance the capabilities of their health monitoring technology. Founded in 2017, PKVitality aims to simplify health management for individuals, particularly those with diabetes, by eliminating the discomfort associated with traditional blood tests.

CARTO

Grant in 2020
CARTO is a leading platform in Location Intelligence, specializing in the analysis and visualization of spatial data. Founded in 2012 by an environmental scientist and visualization experts, the company is headquartered in New York City, with additional offices in Madrid, Seville, and Washington, D.C. CARTO helps businesses optimize processes and make strategic decisions by transforming location data into actionable insights. Its cloud-based service allows data scientists, developers, and analysts to create spatial applications for various platforms, enhancing delivery routes, marketing strategies, and store placements. With a client portfolio of 2,500 customers, including prominent names like Mastercard and Coca-Cola, and a user base exceeding 350,000, CARTO has established itself as a key player in the field. The company is recognized for its innovation by various industry analysts and is backed by notable venture capital firms.

TENSIVE

Grant in 2020
TENSIVE s.r.l. is a biomedical company based in Milan, Italy, founded in 2012. It specializes in the development of innovative prostheses for natural breast reconstruction and augmentation. The company's products utilize biodegradable synthetic biomaterials and feature an internal micro-architecture that mimics blood vessel structures. These vascularized prostheses aim to enhance the quality of life for patients undergoing treatment for breast cancer, offering a solution that reduces the need for recurrent and costly surgical interventions. Through its focus on advanced biomaterials and design, TENSIVE seeks to provide effective and sustainable options for breast reconstruction.

AEInnova

Series A in 2020
AEInnova, founded in 2014 at the Autonomous University of Barcelona, specializes in innovative Internet of Things (IoT) solutions for predictive maintenance. The company was established by a team of PhDs and engineers with expertise in microelectronics and various engineering disciplines. AEInnova's flagship product, InduEye, is a fully battery-less and autonomous device that monitors vibrations, steam traps, and thermal conditions, harnessing energy from waste heat, with future versions incorporating solar and wind power. The technology stands out due to its patented innovation, which enhances performance and enables real-time edge computing while utilizing advanced wireless communication standards. AEInnova's devices are employed in diverse sectors, including oil and gas, aluminum, steel, paper, and water treatment, and feature a sophisticated IoT cloud-based dashboard for data analytics and predictive maintenance. The company has received 31 international awards for its contributions to sustainability and innovation and has secured significant investment, including funding from the European Commission. AEInnova is actively engaged in multiple EU R&D projects focused on energy harvesting and IoT technologies.

Ability Pharmaceuticals

Grant in 2020
Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The company develops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures. Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization.

Aledia

Grant in 2020
Aledia SA specializes in the development and manufacturing of innovative light-emitting diodes (LEDs) utilizing a unique 3D architecture based on gallium-nitride-on-silicon microwires. Founded in 2011 and headquartered in Grenoble, France, with additional subsidiaries in Malacca, Malaysia, and Palo Alto, California, Aledia's technology employs standard 8-inch silicon wafers and existing fabrication processes, allowing for the production of LED chips at a significantly reduced cost compared to traditional planar designs. This technology supports a range of applications, including general lighting, automotive, and display technologies, specifically for mobile and microdisplays used in augmented and virtual reality environments. Aledia's focus on efficient, brighter, and cost-effective displays positions it as a key player in the LED market.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.